MedTrace Logo

Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients

NCT03966664 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2019-06-04

No results posted yet for this study

Summary

Alterations of acid-base equilibrium are very common in critically ill patients and understanding their pathophysiology can be important to improve clinical treatment.

Conditions

  • Sepsis
  • Septic Shock
  • Critical Illness
  • Respiratory Acidosis
  • Respiratory Alkalosis
  • Acid-Base Imbalance

Interventions

DIAGNOSTIC_TEST

In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.

Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

DIAGNOSTIC_TEST

In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood

Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

DIAGNOSTIC_TEST

Biomolecular analysis of plasma proteins.

Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.

Sponsors & Collaborators

  • Charles University, Czech Republic

    collaborator OTHER

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    lead OTHER

Principal Investigators

  • Thomas Langer, MD · Fondazione IRCCS Ca' Granda Hospital, Milano, Italy

  • Antonio M Pesenti, MD · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

  • Frantisek Duska, MD · Third faculty of Medicine, Charles University, Prague

  • Giacomo Grasselli, MD · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

  • Paul Elbers, MD · Amsterdam UMC, Department of Intensive Care Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-03
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Czechia
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03966664 on ClinicalTrials.gov